Pfizer’s Albert Bourla Talks Seagen Acquisition on CNBC’s Mad Money with Jim Cramer
February 9, 2024In December, Pfizer announced it had completed the acquisition of Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines. Seagen is a pioneer in Antibody-Drug Conjugate (ADC) technology, with a culture of innovation and proven track record of delivering revolutionary treatments. With the acquisition, Pfizer has doubled its oncology pipeline and unlocked potential for delivering cancer treatment breakthroughs.
Pfizer’s Chief Executive Officer, Albert Bourla sat down with Jim Cramer on CNBC’s Mad Money to discuss the Seagen acquisition and the company’s expanding cutting-edge, oncology portfolio.
Enduring Focus on Patient Outcomes
Pfizer has a longstanding commitment to helping address the most pressing needs of patients around the world. With one in three people in the U.S. facing cancer in their lifetime[1], the company’s dedication to transformative research and delivering effective therapies for cancer patients is more crucial than ever. Watch below as Albert Bourla expands on how the Seagen acquisition will offer renewed hope to cancer patients.
Prioritizing Premium Science
Pfizer has a flourishing oncology research and development (R&D) presence. With the acquisition of Seagen, the Pfizer Oncology Division is now an integrated team with leadership and workforce from both Pfizer and Seagen – harnessing the combined technological and resource strengths of both companies. This dynamic team will be the engine that drives potential next-generation cancer treatments. Hear Albert’s thoughts on combining the organizations and the deep expertise of Seagen.
Pfizer is a steadfast ally to patients battling cancer worldwide. The Seagen acquisition positions the company to accelerate and deliver the potential next generation of transformative cancer treatments in the near- and long-term.
Forward-looking statements included herein are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. We encourage you to read our reports filed with the U.S. Securities and Exchange Commission (SEC), including the sections captioned “Risk Factors” and “Forward Looking Information and Factors that May Affect Future Results,” for a description of such substantial risks and uncertainties. These reports are available at pfizer.com and the SEC’s website at www.sec.gov.
[1] Cancer. Centers for Disease Control and Prevention. Available here. Accessed Jan. 16, 2024.